The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | Bispecific antibodies in NHL: current insights and ongoing studies
Umberto Vitolo, MD, Candiolo Cancer Institute, FPO-IRCCS, Turin, Italy, discusses the use of the bispecific antibodies glofitamab, epcoritamab and odronextamab in non-Hodgkin lymphoma (HL), focusing on diffuse large B-cell lymphoma (DLBCL). Glofitamab and epcoritamab have shown promising results in third-line and beyond, and even after transplantation or CAR-T. Prof. Vitolo also comments on the good safety profiles of glofitamab and epcoritamab, before describing combination therapies which are being investigated using these agents, such as glofitamab and polatuzumab vedotin. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
